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Introduction: Circular RNAs (circRNAs) have recently been described as novel noncoding regulators of
gene expression. They might have an impact on microRNA expression by their sponging activity. The
detectability in blood of these RNA transcripts has been demonstrated in patients with cancer and car-
diovascular disease. We tested the hypothesis that circulating circRNAs in blood of critically ill patients
with acute kidney injury (AKI) at inception of renal replacement therapy may also be dysregulated and
associated with patient survival.
Methods: We performed a global circRNA expression analysis using RNA isolated from blood of patients
with AKI as well as controls. This global screen revealed several dysregulated circRNAs in patients with
AKI. Most highly increased circRNA-arraybased transcripts as well as expression of the circRNA target
miR-126-5p were conﬁrmed in blood of 109 patients with AKI, 30 age-matched healthy controls, 25 criti-
cally ill non-AKI patients, and 20 patients on maintenance hemodialysis by quantitative real-time poly-
merase chain reaction.
Results: Circulating concentrations of 3 novel circRNAs were ampliﬁed in blood of patients with AKI and in
controls. Circular RNA sponge of miR-126 (or ciRs-126) was most highly altered compared to healthy
controls and disease controls (fold change of 52.1). ciRs-126 was shown to bioinformatically sponge miR-
126-5p, which was found to be highly suppressed in AKI patients and hypoxic endothelial cells. Cox
regression and KaplanMeier curve analysis revealed ciRs-126 as an independent predictor of 28-day
survival (P < 0.01).
Conclusion: Circulating concentrations of circRNAs in patients with AKI are detectable. ciRs-126 may
potentially sponge miR-126-5p and acts as a predictor of mortality in this patient cohort.
Kidney Int Rep (2018) 3, 1144–1152; https://doi.org/10.1016/j.ekir.2018.05.012
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A cute kidney injury is a severe complication incritically ill patients and has been identiﬁed as an
independent risk factor concerning survival.1 Mortality
of patients with AKI in the intensive care unit setting is
highly prevalent and unaltered over recent, years despite
signiﬁcant improvements in supportive care.2 As revealed
by a multicenter study involving a large number of pa-
tients in the intensive care unit, the in-hospital mortality
of patients with AKI exceeds 60%.3 Thus, early
biomarkers enabling the clinician to detect subclinical
AKI identifying patients at particular risk for both death
and prolonged kidney failure after AKI in the setting of
intensive care medicine and renal replacement therapy
(RRT) remains an area of utmost interest. More than 90%
of the human genome is transcribed into RNA transcripts
without protein-coding potential.4,5 These so called non-
coding RNAs (ncRNAs) are arbitrarily separated into long
ncRNAs (lncRNAs,$200 nucleotides) and small ncRNAs
(#200 nucleotides), based on their size. Small RNAs such
as microRNAs (miRNAs) have been extensively studied
over the past years.6–8 miRNA activity has been shown to
be affected by the presence of miRNA sponge transcripts,
the so-called competing endogenous RNA. Circular RNAs,
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which have recently been discovered, are likely a part of
the aforementioned competing endogenous RNA class.
They are endogenously expressed as single-stranded,
covalently closed circular molecules.9 Most circRNAs
are produced in a “back-splicing” reaction, in which a
splice donor site is joinedwith anupstream splice acceptor
site.10,11 Circular RNAs have long been described in
viroids and viruses12,13 but have only recently come into
focus in the mammalian genome.14,15 A landmark study
has proved the release into the blood of patients and
elucidated the biomarker potential of this novel RNA
species.16 Here, it was shown that circRNAs are remark-
ably stable (probably due to resistance to exonucleases
through circularization) and highly expressed compared
to their corresponding linear mRNAs. One of the
intriguing functions of circRNAs is the sponging of
microRNAs, which have been shown to serve as early and
reliable biomarkers of AKI by our group.17 We here pre-
sent the ﬁrst study investigating the pattern of circulating
circular RNAs in blood of critically ill patients with AKI
requiring RRT, and their potential predictive value con-
cerning outcome. Circulating circRNAs as well as poten-
tially regulatedmiR-126-5pwere assessed in RNA isolated
from blood of 109 patients with AKI, 30 age-matched
healthy controls, 25 non-AKI, critically ill patients
and 20 patients on maintenance hemodialysis.
Hsa_circ_0003266 was shown to potentially sponge miR-
126-5p and is therefore referred to as circular RNA sponge
of miR-126 (ciRs-126).
METHODS
Patients and Procedures
This study is a post hoc measurement of prospectively
collected blood samples from the Hannover Dialysis
Outcome (HANDOUT) trial.18 Patients in 7 intensive care
units of the tertiary care center at the Hannover Medical
School with AKI were evaluated for inclusion. The study
protocol was approved by the Hannover Medical School
Ethics Committee and was conducted in accordance with
the Declaration of Helsinki and German Federal Guide-
lines. The inclusion criteria were nonpost-renal AKI
with RRT dependence, indicated by the loss of kidney
function of >30% calculated estimated glomerular
ﬁltration rate (eGFR) with either the Modiﬁcation of Diet
in Renal Disease (MDRD) or Cockcroft–Gault equation
and/or cystatin Cglomerular ﬁltration rate within 48
hours prior to inclusion and oliguria/anuria (<30ml/h>6
hours prior to inclusion) or hyperkalemia (>6.5 mmol/l)
or severe metabolic acidosis (pH<7.15, bicarbonate<12
mmol/l). Exclusion criteria were pre-existing chronic
kidneydisease as deﬁned by eGFR<60ml/min or a serum
creatinine concentration >1.7 mg/dl more than 10 days
prior to initiation of the ﬁrst RRT. In addition, we
considered the presence of an arteriovenous ﬁstula or
dialysis catheter as indicative of chronic kidney disease.
Further exclusion criteria were participation in another
study, consent denial or withdrawal, and need for
extracorporeal membrane oxygenation therapy. Enroll-
ment was performed by attending nephrologists after
obtainingwritten informed consent from a patient or his/
her legal representatives. If the patient was recovering
and able to communicate, he/she was informed of the
study purpose, and consent was required to further
maintain his/her status as a study participant.
After inclusion, the speciﬁc medical condition leading
to RRT initiationwas documented from a list of 4 possible
causes requiring immediate RRT. All patients received a
nutritional intake of at least 25 to 30 kcal/kg per day,
preferentially delivered as enteral nutrition. The pre-
scribed protein intake was >1.2 g/kg per day. Renal
replacement therapy in all patients was performed in a
slow extended dialysis mode using the GENIUS dialysis
system (FreseniusMedical Care, BadHomburg, Germany)
as described in detail elsewhere.19 The dose of the RRT
was tailored according to the patient's individual need,
starting with at least 1 treatment daily. The RRT was
discontinued inpatientsmeeting the following criteria for
renal recovery: urine output >1000 ml/d and/or
increased solute clearance, that is, a decline in
pretreatment serum creatinine concentration with
eGFR >15 ml/min (by the Modiﬁcation of Diet in Renal
Disease or Cockroft–Gault equation, and/or cystatin
Cglomerular ﬁltration rate. Blood was drawn immedi-
ately before the start of RRT. The ﬁrst blood sample was
discarded to avoid ﬁbroblasts and activated platelets.
Serum creatinine and serum C-reactive protein (CRP)
concentrations were determined by an automated
analyzer (Beckman Coulter, Brea, CA). The Sequential
Organ Failure Assessment (SOFA) score20 and Acute
Physiology and Chronic Health Evaluation II (APACHE
II) score21 were obtained for each patient immediately
before initiation of RRT. The presence of sepsis was
deﬁned according to the Society of Critical CareMedicine/
European Society of Intensive Care Medicine/American
College of Chest Physicians/American Thoracic Society/
Surgical Infection Society International Sepsis
Deﬁnitions.22 Acute kidney injury was classiﬁed post hoc
by means of the Risk, Injury, Failure, Loss of kidney
function, and End-stage kidney disease (RIFLE) criteria at
initiation of RRT.23 The Horowitz indexwas calculated as
the ratio of partial pressure of oxygen in blood (PaO2) and
the fraction of oxygen in the inhaled air (FIO2).
A total of 25 critically ill non-AKI patients (12male, 13
female; age 52 years, range 4271 years; 20 patients with
acute myocardial infarction, 2 patients with liver dis-
ease, 3 patients following surgery) as well as 20 patients
on maintenance hemodialysis (11 male, 9 female; age 49
M Kölling et al.: Circulating circRNAs in AKI CLINICAL RESEARCH
Kidney International Reports (2018) 3, 1144–1152 1145
years, range 3962 years) served as disease controls.
Thirty age-matched healthy controls were also included
(16 male, 14 female; age 54 years, 4666 years).
Study Outcomes and Statistical Analysis
The main objective of the study was to analyze the
predictive value of circulating circRNAs concerning
mortality and renal recovery of critically ill patients
with AKI receiving RRT. The study endpoint was
deﬁned as survival 4 weeks after initiation of RRT and
renal recovery (no RRT requirement) in survivors 4
weeks after initiation of RRT.
A detailed Supplementary Materials and Methods
section can be found in the Supplementary Material.
RESULTS
circRNA Expression Analysis in Blood
To assess an impact of AKI on circulating circRNAs, we
conducted a genome-wide expression analysis in RNA
isolated from whole blood of patients with AKI at incep-
tion of RRT (n¼ 15, 3 pools of 5 patients) and healthy age-
matched controls (n ¼ 15, 3 pools of 5 patients). Figure 1
shows that hierarchical clustering analysis clearly
distinguishedAKIpatients fromcontrols, as evidenced by
a speciﬁc signature of signiﬁcantly dysregulated circu-
lating circRNAs. Figure 2a shows a scatter plot and
Figure 2b a volcano plot analysis of identiﬁed circRNAs.
circRNAs that were ﬁnally assessed in thewhole cohort of
patients are marked in Figure 2. The clinical characteris-
tics of the whole cohort of AKI patients (n ¼ 109) are
shown in Table 1. A total of 4161 upregulated circulating
circRNAs were detectable in all groups of the array
cohort, showing a signal intensity >9 and differing be-
tween patients and healthy controls. Supplementary
Table S1 displays the 50 most upregulated circRNAs in
blood of AKI patients, and Supplementary Table S2 lists
the top 50 downregulated circRNAs.
circRNA Validation in Whole Blood
The detection and ampliﬁcation of circRNAs in blood is
challenging due to their low abundance. To investigate
the detectability of dysregulated circulating circRNAs,
we assessed the detectability of the most highly dys-
regulated circRNAs using RNA isolated from whole
blood of patients with AKI in agarose gel electropho-
resis. Here, we found 3 circRNAs to display speciﬁc
bands of correct size, including ciRs-126, hsa_-
circ_0045881, and hsa_circ_0001177. We then per-
formed real-time polymerase chain reaction analysis in
a subset of patients with AKI (n ¼ 10). These 3 novel
transcripts showed clean ampliﬁcation curves, showed
speciﬁc curves in melting curve analysis, and were
undetectable in water controls without template. To
ascertain that transripts were speciﬁcally detected in
whole blood, we sequenced transcripts in these pa-
tients after polymerase chain reaction ampliﬁcation,
which conﬁrmed that circRNAs were correctly ampli-
ﬁed and detectable.
ciRs-126 Is a Biomarker of AKI
We next analyzed ciRs-126, hsa_circ_0045881, and
hsa_circ_0001177 in the whole cohort of patients with
AKI (n ¼ 109) as well as disease controls (non-AKI, criti-
cally ill disease controls, n¼ 25; patients on maintenance
hemodialysis, n ¼ 20) and age-matched healthy in-
dividuals (n ¼ 30). As shown in Figure 3a, ciRs-126 was
signiﬁcantly increased compared to that in healthy con-
trols and disease controls, underlining the speciﬁcity as a
biomarker in AKI (P< 0.001). Both hsa_circ_0045881 and
hsa_circ_0001177 were signiﬁcantly increased compared
to those in healthy controls, but not compared to those in
disease controls (Figure 3b and c). Baseline ciRs-126
correlated with SOFA score (r ¼ 0.2, P ¼ 0.02), length of
need for respirator therapy (r¼0.4,P¼ 0.01), and length
of stay on the intensive care unit (r ¼ 0.5, P < 0.01).
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Figure 1. Hierarchical cluster analysis of dysregulated circulating
RNAs (circRNAs) in blood of patients with acute kidney injury (AKI) and
healthy controls. Red colors represent upregulated circRNAs; green
colors represent downregulated circRNAs. hsa_circ_0003266 (or ciRS-
126),hsa_circ_0045881,and hsa_circ_00011776aremarkedby anarrow.
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ciRs-126 Predicts Survival in AKI
Patients were grouped as survivors and nonsurvivors at
4 weeks after initiation of RRT. Patient groups were
comparable with respect to baseline demographics and
the proportion of RIFLE categories (Table 1). A total of 40
patients died in our cohort. Concentrations of circulating
ciRs-126 were signiﬁcantly (P < 0.01) increased in
nonsurvivors. To investigate the prognostic potential of
circulating ciRs-126 concentrations at initiation of RRT
with regard to overall mortality, we performed univar-
iate Cox proportional hazards analyses. ciRs-126 was
subjected to natural logarithmic transformation. In our
cohort of 109 critically ill patients with AKI, ciRs-126
concentrations, major surgery, sepsis, shock, APACHE
II, SOFA, and Horowitz score showed prognostic
signiﬁcance at a 10% level and were subsequently
subjected to multivariate Cox regression analysis
(Table 2). Only APACHE II score (P¼ 0.06) and ciRs-126
concentrations (P < 0.001) remained independent pre-
dictors of survival in multivariate analysis. In receiver
operating characteristic curve analysis ciRs-126 levels
yielded an area under the receiver operating character-
istic curve value of 0.92 (SEM: 0.02; 95% conﬁdence
interval: 0.880.97; P < 0.0001). In receiver operating
characteristic curve analysis, we deﬁned a cut point of
1.165 relative expression by DDCt analysis with 91%
sensitivity and 74% speciﬁcity. Figure 3d illustrates the
KaplanMeier survival curve 4 weeks after initiation of
RRT stratiﬁed to ciRs-126 concentrations above and
below the median. A log rank test conﬁrmed the statis-
tical signiﬁcance for circulating ciRs-126 concentrations
(P < 0.001). Figure 3e shows receiver operating char-
acteristic curve analysis.
ciRs-126 as a Potential miRNA Sponge
As identiﬁed by the Arraystar miRNA target prediction
software (Arraystar, Rockville, MD), which is based on
the TargetScan and miRanda algorithm, miRNA bind-
ing elements were identiﬁed regarding miR-126-5p in
the ciRs-126 sequence (Supplementary Figure S1). To
test the potential interaction between ciRs-126 and its
target miRNA, miR-125-5p was ampliﬁed in the whole
cohort of patients and was found to be highly sup-
pressed in AKI patients compared to controls, indi-
cating its potential regulation by ciRs-126 (Figure 3f).
We therefore refer to hsa_circ_0003266 as circular RNA
sponge for miR-126 (ciRs-126).
circRNAs and miR-126-5p Are Regulated in Cells
Endothelial cells and proximal tubular epithelial cells
are most highly affected by AKI. Accordingly, we
assessed the expression of the 3 novel circRNAs in
these cells under hypoxic conditions. All 3 transcripts
are signiﬁcantly upregulated in hypoxic endothelial
cells, whereas only ciRs-126 and hsa_circ_0001177 were
induced in hypoxic proximal tubular epithelial cells
(Figure 4a–c and Figure 4e–g). miR-126-5p is an
endothelial-speciﬁc microRNA. Accordingly, miR-126-
5p was assessed in endothelial cells in vitro and was
found to be highly suppressed by hypoxia (Figure 4d).
DISCUSSION
Our study is the ﬁrst evaluation of circulating circR-
NAs in any cohort of patients with kidney disease. We
were able to show the following: (i) circulating circR-
NAs in whole blood of critically ill patients with AKI
were detectable; (ii) circulating circRNA concentrations
Figure 2. Scatter plot (a) and volcano plot analysis (b) of deregulated circulating RNAs (circRNAs) in blood of patients with acute kidney injury
(AKI) and healthy controls. Identiﬁed circRNA are further marked: ciRS-126 (circle), hsa_circ_0045881 (triangle), and hsa_circ_0001177 (square).
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speciﬁcally identiﬁed patients with AKI; (iii) baseline
concentrations of ciRs-126 correlated with parameters
of disease severity; (iv) baseline concentrations of
circulating ciRs-126 were increased in nonsurvivors
compared to survivors; (v) ciRs-126 was identiﬁed as a
strong independent prognostic factor for 28-day-survival
in the multivariate Cox proportional hazards regression
analysis and KaplanMeier curve analysis; and (vi)
circulating levels of miR-126-5p were highly suppressed
in AKI patients and endothelial cells.
circRNAs show widespread distribution and diverse
functions. They arew100 nucleotides in length and are
highly present in the eukaryotic transcriptome and
abundant in exosomes.24 As stated in the introduction,
circRNAs are likely produced in a “back-splicing” reac-
tion, in which a splice donor site is joined with an up-
stream splice acceptor site, thus forming a circular
structure in which the 30- and 50-ends are covalently
linked.10,11 These circRNAs are termed “exonic” circR-
NAs because they arise from known exons at annotated
splice sites, as opposed to “intronic” circRNAs,
containing a 20-50 carbon linkage at the branch point
stemming from introns. Owing to their circular structure
and the absence of a 50 cap, it is currently believed that
circRNAs are not translated into protein.25 A character-
istic element of circRNAs is the “head-to-tail” splice
junction (due to backsplicing), in which exons are orga-
nized in reverse order compared to their chromosomal
localization. One likely cellular function of circRNAs is
the binding and sequestering of miRNAs,24,26 but this
interaction might only be observed in circRNAs with a
high number of binding sites for a speciﬁc miRNA. For
instance, ciRs-7 (circular RNA sponge formiR-7) has been
identiﬁed inmouse brain and shown to expressmore than
70 conserved miR-7 target sites.26 Moreover, it is highly
associated with Argonaute (AGO) proteins in a miR-
7dependent manner.26 It strongly suppresses miR-7
activity, resulting in increased levels of miR-7 targets.26
circRNAs likely exert further functions, as has been
described for lncRNAs. Because circRNAs are less sus-
ceptible to exonuclease activity (due to their circular
structure), they exhibit signiﬁcantly longer half-lives
than linear RNAs,24 suggesting their ideal role as stable
biomarkers in body ﬂuids of patients.
We identiﬁed several putative binding sites of miR-
126-5p in the sequence of ciRs-126. miR-126 has previ-
ously been shown to lead to resolution of AKI in mice.27
Hematopoietic overexpression of miR-126 increased
neovascularization, led to an improvement of kidney
function, and increased numbers of bone
marrowderived endothelial cells. The numbers of
circulating Lin()/Sca-1(þ)/cKit(þ) hematopoietic stem
and progenitor cells were increased.27 Deactivation of
miR-126was shown to induce a pseudohypoxia state due
to increased HIFa expression in kidney cancer. Serpin
Family E Member 1 (SERPINE1) was identiﬁed as a
miR-126-5p target regulating cell motility.28 Chronic
heart failure was signiﬁcantly associated with lower
circulating levels of miR-126-5p.29 Lack of miR-126-5p
reduced endothelial cell proliferation by derepression
of the Notch1 inhibitor delta-like 1 homolog (Dlk1).30
Currently, we are unable to provide deﬁnitive proof
that ciR-126 indeed sponges miR-126-5p. Based on bio-
informatic sequence homology and level of regulation in
our analyses, we hypothesize that it may be regulated by
ciRs-126. Future studies will address the experimental
proof of binding interaction.
There are several distinct possible sources of circu-
lating circRNAs. It was previously shown that circRNAs
are physiological components of neutrophils, B-cells,
and hematopoietic stem cells, conﬁrming that they may
be derived from these circulating cells.31 It is moreover
conceivable that they might also be secreted into the
extracellular space and transported in exosomes or small
vesicles, as has been shown for microRNAs. This has
Table 1. Demographic, clinical, and laboratory characteristics of
patients
Characteristic Total Survivors Nonsurvivors P value
Patients, n 109 69 40 0.6
Male, n (%) 64 (59) 40 25
Female, n (%) 45 (41) 29 15
Discipline of ICU admission 0.4
Medicine, n (%) 46 (42) 27 (39) 19 (48)
General surgery, n (%) 27 (25) 16 (23) 11 (28)
Cardiac surgery, n (%) 36 (33) 26 (38) 10 (24)
Age, yr 52 (40–63) 52 (44–63) 51 (37–63) 0.8
BMI, kg/m2 25 (22–28) 25.4 (22–28) 24.7 (22–28) 0.6
Indication for RRT
eGFR loss >30% 93 59 34 0.9
Oliguria/anuria 71 46 25 0.8
Metabolic acidosis 8 4 4 0.4
Hyperkalemia 6 2 4 0.1
SOFA score 13 (10–15) 14 (11–15.5) 13 (10–15) 0.7
Renal 2 (1.5–3) 2 (1–2.5) 2 (2–3) 0.02a
Coagulation 1 (0–2) 2 (0–2) 1 (0–2) 0.6
Cardiovascular 4 (0.5–4) 4 (2–4) 3 (0–4) 0.2
Nervous system 4 (3–4) 4 (3–4) 4 (3–4) 0.9
Respiratory system 2 (1–3) 2 (1–3) 2 (2–3) 0.8
Liver 2 (0–2) 2 (0–3) 2 (0–2) 0.4
RIFLE class 0.1
Risk, n (%) 10 (9) 9 (13) 1 (3) 0.07
Injury, n (%) 15 (14) 9 (13) 6 (15) 0.8
Failure, n (%) 84 (77) 51 (74) 33 (82) 0.3
APACHE II score 34 (27–36) 33 (26–36) 35 (29–39.8) 0.6
CRP (mg/l) 113 (56–197) 82 (46–191) 145.5 (67–211.5) 0.2
MAP (mm Hg) 75.5 (67–90) 77 (70–93) 74 (64–86) 0.3
Heart rate (bpm) 100 (85–110) 99 (84–109) 100 (89–111) 0.3
APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index;
CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; ICU, intensive care
unit; MAP, mean arterial blood pressure; n, number of patients; RIFLE, Risk, Injury,
Failure, Loss of kidney function, and End-stage kidney disease; RRT, renal replacement
therapy; SOFA, Sequential Organ Failure Assessment.
aSignificant.
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been suggested recently.32 Platelets may be another
important source of circRNAs, as has recently been
described.33,34 CircRNAs have been shown to serve as
noninvasive diagnostic tools in patients with athero-
sclerosis,15 disorders of the central nervous system,35
degenerative diseases,10 and cancers.32,36
As has been previously discussed for microRNAs
and lncRNAs, a “housekeeping” circRNA has not been
identiﬁed in bodily ﬂuids of patients, which is why a
strategy was chosen to normalize circulating circRNAs
to recombinant Caenorhabditis elegans miR-39 (cel_miR-
39).6,7,17,37–39 Cel_miR-39 was supplemented to samples
during the RNA isolation process.
We focused on the novel circRNA transcript ciRs-126,
which we identiﬁed as a speciﬁc biomarker of AKI.
A speciﬁc role for this circRNA has not yet been
described.We herein provide evidence of ciRs-126 as an
independent prognostic survival factor in AKI. Of note,
miR-126-5p might be a downstream interaction partner
mediating the effects of our newly identiﬁed circRNA.
Intriguingly, the linear counterpart Leucine-rich re-
peats and Ig-like domains protein 1 (LRIG1) of ciRs-126
might have an important role in acute kidney injury. It
encodes a transmembrane protein that has been shown to
interact with receptor tyrosine kinases of the EGFR
family,40 tyrosine-protein kinase Met,41 and RET proto-
oncogene.42 Met has been shown to be highly important
for early cytoprotection and regeneration in ischemic
AKI.43 Activation of EGFR was demonstrated to accel-
erate recovery from acute nephrotoxic kidney injury.44
Table 2. Univariate and multivariate Cox regression analysis for survival
Variable
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
circRNA_ln 2.678 2.056–3.487 <0.001a 2.610 2.012–3.385 <0.001a
Sepsis (yes/no) 2.425 1.341–4.388 0.003a
Surgery (yes/no) 2.074 1.088–3.954 0.03a
SOFA score 1.167 1.064–1.280 0.01a
APACHE II score 1.046 1.005–1.088 0.03a 1.040 0.999–1.083 0.06a
Horowitz score 0.997 0.994–1.000 0.03a
APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, conﬁdence interval; circRNA_ln, log transformed hsa_circ_0003266; HR, hazard ratio; SOFA, Sequential Organ Failure
Assessment.
aP < 0.1.
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Figure 3. Concentrations of circulating (a) ciRS-126, (b) hsa_circ_0045881, and (c) hsa_circ_0001177 in patients with acute kidney injury (AKI)
compared to healthy controls and non-AKI, critically ill disease controls and patients on maintenance hemodialysis. (d) KaplanMeier curve
analysis and log rank testing in AKI patients above and below median during an observation of 4 weeks concerning ciRS-126. (e) Receiver
operating characteristic curve (ROC) analysis identifies a cut point of 1.165 relative expression with an area under the curve (AUC) of 0.92, a
sensitivity of 91%, and a specificity of 74% regarding ciRS-126. (f) Circulating levels of miR-126-5p in patients with AKI. ***P < 0.0001, **P < 0.01,
*P < 0.05. ICU, intensive care unit; HD, hemodialysis; NS, not significant.
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Because miR-126 has been shown to control endothelial
cell homeostasis30 as well as hypoxia signaling28 and has
also been shown to be an important protective micro-
RNA in AKI,27 we hypothesize that ciRs-126may be part
of signaling cascade involving LRIG andmiR-126, which
may have implications as a cytoprotective mechanism in
AKI, which is released into the circulation to counteract
progressive kidney injury.
Important limitations to our study should be
mentioned. First, we do not outline insights into associ-
ated molecular mechanisms of ciRs-126 release. In-depth
basic science studies are warranted to assess the speciﬁc
function of ciRs-126 in the kidney. Second, our study
represents merely a single-center experience with a
limited number of patients. Larger independent cohorts
are highly desirable to validate our ﬁndings. Finally, most
patients recruited in our study were patients with severe
kidney injury (RIFLE stage 3). It would be desirable to
include more patients with mild and moderate kidney
injury (RIFLE stages 1 and 2) in future studies.
In conclusion, our study is the ﬁrst to provide in-
sights into the concentrations of circulating circRNAs
in critically ill patients with AKI. A large number of
circulating circRNAs can be reliably detected in blood
of AKI patients. We identiﬁed the novel circRNA
transcript ciRs-126 as a strong and independent pre-
dictor of mortality in critically ill patients with AKI.
Circulating ciRs-126 may therefore be an intriguing
RNA-based biomarker that might reﬂect miRNA dys-
regulation noninvasively.
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